The acquisition is part of an effort to strengthen Allergan’s skin care division, according to the report.
The purchasing price values Vitae at $21 a share, compared with the company’s closing price of $8.10 per share on Tuesday, according to the report. Shares of Vitae spiked to $20.93 in premarket trading Wednesday, and Allergan shares rose 0.8 percent.
Under the deal, Allergan will acquire a drug currently in mid-stage trials that is designed to treat psoriasis, a disease that causes itchy dry skin patches, and other autoimmune disorders, according to the report.
More articles on supply chain:
Market exclusivity main factor in high drug prices, study finds
How can the Internet of (very valuable) things reduce costs in healthcare?
US faces shipping container shortage following Hanjin bankruptcy
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
